Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis because it is often detected at an advanced stage, and drug resistance interferes with treatment. However, the mechanism underlying drug resistance in PDAC remains unclear. Here, we investigated metabolic changes between a par...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara-Tani, Rina, Sasaki, Takamitsu, Takagi, Tadataka, Mori, Shiori, Kishi, Shingo, Nishiguchi, Yukiko, Ohmori, Hitoshi, Fujii, Kiyomu, Kuniyasu, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323155/
https://www.ncbi.nlm.nih.gov/pubmed/35887170
http://dx.doi.org/10.3390/ijms23147824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323155/
https://www.ncbi.nlm.nih.gov/pubmed/35887170
http://dx.doi.org/10.3390/ijms23147824

Ejemplares similares